Introduction
Hemoptysis is a common and important symptom in clinical practice and accounts for 10e15% of all pulmonary consultations. Hemoptysis can range from blood streaking of sputum to gross blood without any accompanying sputum. The symptoms are distressing for the patient and frequently raise concern about serious underlying disorders, including lung cancer. 1 Therefore, a thorough evaluation of a patient with even a small amount of hemoptysis is important.
Diagnosing the cause of hemoptysis is often difficult, more so in patients presenting with a normal or nonlocalizing chest radiograph. In 1985, Adelman et al. referred to a condition called 'cryptogenic hemoptysis,' which was defined as no clear cause of bleeding despite a thorough evaluation. 2 They estimated that this occurs in about 30% of all hemoptysis patients and suggested that this condition is related most often to acute or chronic bronchial inflammation, occult bronchiectasis, inactive tuberculosis, pulmonary vascular abnormalities, and coagulation abnormalities. 2 A Korean study reported the clinical outcomes of hemoptysis patients with normal chest radiographs in 1993. 3 Initial bronchoscopy was performed in all patients and produced a diagnosis in 10% (8/80) of patients. Among the remaining 72 patients, chest computed tomography (CT) or bronchography was performed to evaluate the cause of hemoptysis. However, only 22% (16/72) of patients had a chest CT because CT was not readily available at that time. The causes of hemoptysis in this study were listed as endobronchial cancer, chronic bronchitis, endobronchial tuberculosis, bronchiectasis, and catamenial hemoptysis. 3 CT and bronchoscopy are now widely accepted in the screening of hemoptysis patients with normal chest radiographs. The technology and resolution power have improved markedly. Magu and colleagues reported that a chest CT provided diagnostic information in 16 (53%) of 30 patients with normal chest radiographs. 4 Other authors have reported abnormalities in 39e60% of cases. Many studies have suggested that CT and bronchoscopy are complementary methods, and have recommended that both tests are used in hemoptysis patients with a nonlocalizing chest radiograph. However, there has been little research on the clinical course of patients whose chest CT does not show an obvious cause of hemoptysis.Most articles included patients with hemoptysis whose simple radiographs were normal, but did not focus on patients with a normal CT. However, in clinical practice, a chest CT cannot identify a lesion as the cause of hemoptysis in some patients, and it can be difficult to manage these patients and to explain the clinical course and prognosis of their symptoms.
The aim of this study was to describe the clinical course and long-term outcomes of patients with hemoptysis whose chest CT shows no lesion to explain the hemoptysis.
Methods
This study included patients who visited Seoul National University Hospital and Bundang Seoul National University Hospital from January 2003 through October 2009. The included patients had a chief complaint of subjective hemoptysis or blood-tinged sputum but had no explainable lesions for hemoptysis on chest CT. The results of the chest CT were reported by a radiologist.
We retrospectively reviewed the medical records, chest CT, and bronchoscopy findings of the patients. From the medical records, the following clinical variables were collected: age, sex, smoking history, comorbidities, duration of follow-up, recurrence of hemoptysis, newly developed significant findings during the follow-up period, and the final diagnosis based on clinical, radiological, and histological findings. All patients underwent bronchoscopic evaluations by the pulmonology doctors in the fellowship under the supervision of senior professors. In cases without evidence of bleeding in bronchoscopy, the patients visited an otolaryngologist or dentist, and some were examined by esophagogastroduodenoscopy to exclude intraoral or nasopharyngeal bleeding. This retrospective data collection was approved by the institutional review board of Seoul National University (IRB No: H-0904-048-278) and has therefore been performed in accordance with the Declaration of Helsinki.
The Statistical Package for the Social Sciences (SPSS) version 10.0 (SPSS Corporation, Chicago, IL) was used for statistical analysis. The patients' clinical variables were expressed as mean AE standard deviation (SD) and range. We compared the clinical variables between the recurrence group and nonrecurrence group using Student's t test and the c 2 test. Logistic regression was used for multivariate analysis.
Results

Clinical features
Two hundred and twenty-eight patients, whose mean age was 51.6 years, were included in this study; about 56% of these patients had never smoked (n Z 129), and 26 (11.4%) had been treated adequately for pulmonary tuberculosis previously. The baseline characteristics and comorbidities of the patients are listed in Table 1 .
CT findings
The chest CT findings of these patients were normal (36.0%) or included granulomas or tiny nodules (32.9%), ground glass opacity (16.7%), linear atelectasis (15.8%), small lymph node enlargement (5.7%), and other conditions (8.8%). The CT findings are listed in Table 2 .
Bronchoscopic findings
Bronchoscopy was performed in all patients. We found the possible cause of bleeding in 37 (16.2%) patients (positive for possible causes of hemoptysis in Table 3 ) and the bronchoscopic findings showed no cause of bleeding (negative for possible causes of hemoptysis in Table 3 ) in the other 191 patients (83.8%).
One of the patients who showed an elevated mucosal lesion in bronchoscopy was diagnosed with squamous cell lung cancer by bronchial washing cytology, and he received an operation. The results of the biopsy or washing cytology in the other three patients who showed an elevated mucosal lesion indicated chronic inflammation.
Clinical course of the patients
Thirty-seven patients in the group with positive findings on bronchoscopy were followed for a mean duration of 768 days. Hemoptysis recurred in 35.1% patients, and the mean duration for the first recurrence was 207 days (Table 4 and Fig. 1 ). One of these patients developed a new nodule, which was detected by chest CT one year after the first visit; this was considered as an arteriovenous malformation, and the patient was free of recurrence.
The other 191 patients in the group with negative findings on bronchoscopy visited an otolaryngologist (151 patients) or dentist (175 patients), and some of them received an esophagoduodenoscopy (88 patients) to exclude intraoral or nasopharyngeal bleeding. Twenty-seven patients had sinus or dental problems, and 20 patients were using antiplatelet or anticoagulant agents. Among these patients, four had both sinus problems andwere taking antiplatelet drugs. In total, 43 patients were thought to have oropharyngeal bleeding or anticoagulation effects.
One hundred and forty-eight patients (excluding the 43 patients from the group with negative findings on bronchoscopy) were thought to have episodes of real hemoptysis. Among these patients, hemoptysis recurred in 19.6% patients, and the mean time for recurrence was 410 days (Table 4 and Fig. 1 ). During the follow-up period, pulmonary tuberculosis developed in one patient without recurrence of hemoptysis. The final diagnosis of the cause of hemoptysis was made in six patients, catamenial hemoptysis in five, and polyarteritisnodosa in one. Except for these six patients, the causes for hemoptysis in the other patients remained unknown, and no patients developed a malignancy during the follow-up.
The time to the first recurrence of the symptom was significantly shorter and the recurrence rate was significantly higherin the group with positive findings than in the group with negative findings on bronchoscopy (Table 4 ). In KaplaneMeier estimates (Fig. 2) , the recurrence rate was 19.5% (95% CI, 0.09e0.41) in the group with positive findings and 4% (95% CI, 0.01e0.99) in the group with negative findings on bronchoscopy over a standard time interval (500 days).
After excluding the 43 patients who were thought not to have real hemoptysis, we compared the clinical variables in patients who experienced recurrence (n Z 42) and who did not experience recurrence (n Z 143). The mean follow-up was significantly longer in the recurrence group (1017.8 AE 715.2 days vs. 668.6 AE 714.7 days, P Z 0.006). The percentage of patients with new findings or who received a final diagnosis of the cause of hemoptysis during the follow-up period was significantly higher in the recurrence group (11.9% vs. 2.1%, P Z 0.016) and the differences in these two variables were remained significant in the multivariate analysis.
Discussion
We tried to evaluate the clinical course of patients with hemoptysis who did not show a demonstrable cause in their chest CT. We found the possible cause of hemoptysis in 16.2% of the 228 patients using the initial bronchoscopy. Forty-three patients were classified as having oropharyngeal bleeding or using anticoagulants after bronchoscopy, visiting an otolaryngologist or dentist, and receiving an esophagoduodenoscopy. During the follow-up period, the final diagnosis of the cause of hemoptysis was made in six patients (catamenial hemoptysis in five and PAN in one), and new findings were detected in two patients (pulmonary tuberculosis in one and a small nodule in the other). Among the 228 patients with hemoptysis and no demonstrable cause in chest CT, we could find the cause in 86 (37.7%) patients, although it was not real hemoptysis in 43 patients. The cause in the other 142 patients (62.3%) remained unknown during the follow-up period.
In the study of Thirumaran et al, 8 which included patients with normal chest X-ray, the cause of hemoptysis remained unexplained in 5.8% after CT and bronchoscopic evaluation. Because we included patients who had already been evaluated by CT the number of patients with an unknown cause of hemoptysis was higher in our study than in the study by Thirumaran et al. Nevertheless, in the patients whose CT findings were negative, we could find the cause in 37.7% through a careful history and full examination including bronchoscopy. We believe that in patients with hemoptysis whose chest CT is negative for the cause of hemoptysis, the history, physical examination, bronchoscopy, and evaluation for upper oropharyngeal bleeding are essential parts of the diagnostic work-up.
In this study, the initial bronchoscopy gave a diagnosis in 16.2% of patients, and one (0.4%) of them was diagnosed with lung cancer by bronchial washing cytology during the initial episode of hemoptysis. Previous studies found a 0e16% cancer detection rate for bronchoscopy in patients with hemoptysis and normal chest radiograph. 9e11 Kaminski et al. 12 reported a cancer detection rate of up to 21% and 83% diagnostic value for nonspecific bronchitis and tuberculosis for a single bronchoscopy in patients with hemoptysis and normal chest radiograph. These studies included patients whose chest radiographs were normal but did not focus on a CT, and the diagnostic value of bronchoscopy was higher than in our study, which included patients whose chest CT was normal.
Herth et al. 13 reported the clinical outcomes of patients with hemoptysis of unknown etiology in a retrospective study that included 722 patients with hemoptysis. One hundred and thirty-five patients (19%) had hemoptysis of unknown origin. These 135 patients were observed for a mean of 6.6 years, and lung cancer developed in 6% during the follow-up period.
In our study, the overall mean follow-up period was 751 days (2.1 years), and no patients developed lung cancer during the follow-up period. In contrast to the study by Herth et al., the relatively short follow-up duration in our study may be the reason for the low detection rate of malignancy (2.1 years vs. 6.6 years). However, in the study by Herth et al., an initial chest CT was not performed in all patients as in our study, and the chest CT was obtained at the discretion of the evaluating pulmonary physician, 13 suggesting the possibility that cases of lung cancer were not detected during the initial episode of hemoptysis. This is supported by the finding that seven cases of lung cancer were detected at an unresectable stage at the time of diagnosis.
Hemoptysis of unknown origin is usually diagnosed when no clear cause of bleeding is evident despite thorough evaluation. 2 In previous studies, these cases accounted for 7e25% of hemoptysis cases 2, 6, 13 and the clinical course was usually minor and benign.
2,14 Adelman et al. 2 evaluated the clinical outcomes of 67 patients with hemoptysis and nonlocalizing chest roentgenogram and nondiagnostic bronchoscopy examination. During a 38 AE 22 (SD)-month period (3.1 AE 1.8 years), 85% of patients remained well without evidence of active tuberculosis or malignancy. One patient (1.4%) developed bronchogenic carcinoma 20 months after bronchoscopy, and hemoptysis recurred in eight patients (11.9%).
More recently, in 2007 Savale et al. 15 prospectively studied the clinical course of 73 patients with cryptogenic hemoptysis after performing X-ray, bronchoscopy, and a CT scan. The mean follow-up duration was 3.9 (AE2.9) years. No cancer developed, and hemoptysis recurred in only 10 patients (13.7%). In our study, the overall recurrence rate was about 20%, which is slightly higher than that in the study by Savale et al. We speculate that differences in the included patients and treatment strategies might explain the differences in results between their study and ours. The study by Savale et al. included only patients admitted to a respiratory intermediate care ward and intensive care unit. Initial bronchial arterial embolization was performed in 53% of patients to control bleeding. In other words, there were more patients with severe hemoptysis in the study by Figure 2 KaplaneMeier curve of recurrence free rate in two groups with positive and negative findings on bronchoscopy.
Savale et al. and this bleeding required active control. By contrast, only 11 patients (4.8%) underwent embolization during the initial episode of hemoptysis in our study. Most patients experienced light symptoms and had no need for active invasive treatment. Consistent with the studies mentioned above, no patients developed a malignancy during the follow-up in our study despite the 20% recurrence rate, even in negative bronchoscopy patients. We speculate that the clinical presentation of hemoptysis without demonstrable cause in a full examination including chest CT and bronchoscopy usually comprises minor to chronic bleeding with a benign course.
A 1993 Korean study 3 showed that bronchiectasis, endobronchial or pulmonary tuberculosis, bronchogenic carcinoma or metastatic cancer in the bronchus, and catamenial hemoptysis are major causes of hemoptysis in patients with a negative chest radiograph. Because our study included patients with negative CT findings, these causes (infection, lung cancer, and bronchiectasis), which are easily detected by chest CT, were excluded initially. Thus, the causes of hemoptysis that we detected differed considerably from those in previous studies; endobronchial carcinoma, small minor abnormalities in the bronchus that are not detected easily by CT.
In our study, the follow-up duration was significantly longer in the recurrence group than in the nonrecurrence group. The number of cases for which the final diagnosis was made during the follow-up was significantly higher in the recurrence group. These findings suggest that the higher the frequency of hemoptysis, the more willing patients are to visit the doctors and attend regular follow-up, meaning that the diagnosis or new findings will be discovered in more patients during the follow-up period. We think that the recurrence of symptoms should alert the physician to the possibility of undetected potential pathological findings.
This study has several limitations. First, we could not get the exact amount of hemoptysis of all the patients from the chart review. This is the limitation of this retrospective design. However, most patients in this study experienced several episodes of blood-tinged sputum and were followed up in the outpatient clinic. Only a small portion of patients (4.8%) had massive hemoptysis and they received embolization for the control of bleeding. From the available data records, we found that the roughly estimated amount of hemoptysis was 7.9 cc (AE12.4).
Second, we did not include all patients with hemoptysis visiting our hospitals. We included only the patients with hemoptysis who had both chest CT and bronchoscopy. In clinical practice in our hospital, we usually perform a screening chest CT scan for patients with hemoptysis, especially when there is no definite abnormality in simple chest X-ray. When there is a definite lesion in simple chest X-ray which could be a cause of hemoptysis such as bronchiectasis or tuberculosis, chest CT scan is performed case by case. Actually there were 26 patients with hemoptysis who did not undergo chest CT scan during the study time interval.This can be a selection bias in this study. Third, it was too difficult to make sure that excluded 43 patients did not have real hemoptysis. However, they had no evidence of bleeding focus in both bronchoscopy and chest CT initially and 36 patients (83%) got relieved of symptom after discontinuation of antiplatelet agents or orophagryngeal treatment during initial episode of bleeding. In addition, three recurred patients showed negative finding for hemoptysis in follow-up chest CT again but revealed chronic sinusitis with recurrent nasal polyps in sinus examination. Therefore we assumed that these cases might have not real episodes of hemoptysis.
In summary, we evaluated patients with hemoptysis who showed no demonstrable cause of symptoms in chest CT. We found the possible causes in some of patients through the initial bronchoscopy and confirmed lung cancer in one patient (0.4%). In addition, in 37.7% of all patients, the cause of symptoms was identifiable using bronchoscopy, careful history, and upper oropharyngeal evaluation. The recurrence rate was significantly higher in patients with positive bronchoscopy findings than in those with negative bronchoscopy findings. Although about 20% of patients with negative bronchoscopy findings developed recurrence, the clinical course of these patients was benign and no cancer developed during the follow-up period.
